Agenda
2022 agenda
Please check back regularly as we continue to add more details around our sessions and confirmed speakers. Sessions and topics are subject to change.
monday, november 14
5:00 PM CDT
Welcome Reception
P6 at The LINE
tuesday, november 15
9:00 AM CDT
Opening Keynote: Unified Platforms for Health and Science
L7|ESP is rapidly becoming a key component of Digital Transformation in science + health organizations. The talk will cover the fundamental concepts of the L7|ESP unified platform and its evolution over the past few years and the roadmap moving forward.
Vasu Rangadass, Ph.D., President and CEO, L7 Informatics
Waller D
9:30 AM CDT
Unified Platforms, Digitalization of CGT Platforms, Lab of the Future
“Lab of the Future” (LoF) has recently become a popular topic for modernizing laboratories. While performing upgrades to laboratory informatics systems and adopting “hyped” technologies such as IoT, AI/ML, AR/VR and blockchain may support modernization on the surface, many existing LoF strategies run the risks of only delivering incremental value.
Your LoF strategies, especially for CG&T initiatives, need to have a deeper impact to survive executive scrutiny and must put an augmented data analytics strategy at the center. A LoF strategy must also enable a digital twin for the lab at multiple levels- with impacts on lab assets, personnel, and systems. As businesses transform, all aspects of business, including the laboratory need to support digital optimization and transformation. In this session, we review the meaning of digitalization, the technologies important for achieving LoF, and outline strategic steps for ensuring your “LoF” strategy will be aligned to deliver true value in the Digital Era.
Michael Shanler, Distinguished VP Analyst, Gartner
Waller D
10:00 AM CDT
Morning Coffee and Networking
Foyer
10:30 AM CDT
Scaling Precision Diagnostics – Lessons from the Trenches
Almost a decade into genomics going mainstream, the community still feels challenged in basic areas surrounding EHR connectivity, clinical phenotypes, data provenance, data governance, state management, integrations, assimilation of newer technology platforms, scalability and speed to market. We will look at some of the challenges and learnings to understand what it takes to succeed in this age of precision medicine.
Ray Veeraraghavan, Executive Director – Advanced Diagnostics Technology, US, Quest Diagnostics
Waller D
11:00 AM CDT
Panel Discussion: Digital Transformation in Manufacturing
Due to the explosive growth in the Cell and Gene Therapy market and increased demand for manufacturing capacity, significant bottlenecks have become both realized and felt by the drug sponsors and their manufacturers. With an expected CGT market growth of 40% per annum and new regulatory pathways accelerating drug commercialization, the CGT industry must adapt to the changing climate and demand and embrace digital solutions within their operations. This panel comprised of industry experts focuses on those bottlenecks manufacturing bottlenecks and where investment in next-generation digital tools and technologies are warranted to overcome the manufacturing hurdles to bring CGT products to the clinic.
Moderator:
Steven Barash, VP Strategy & Development, L7 Informatics
Panelists:
Michael Shanler, Distinguished VP Analyst, Gartner
Trent Carrier, Ph.D, MBA, Chief Operating Officer, L7 Informatics
Waller D
12:00 PM CDT
Lunch
Foyer
1:10 PM CDT
Starting the Digital Journey on the Right Foot
Industries and its leaders are progressing towards digital transformation which is an integral requirement and that includes the Lifesciences industry as well. The scope of digital transformation in the Lifesciences industry can be expanded based on an organization’s position on the digital maturity ladder. Digital convergence is a milestone on this journey towards digital maturity and this can be achieved by way of digital thinking. However, looking at the current state of transformation, there are various gaps that need to be addressed including those in data management, the various missteps in architecture including data and systems, which impacts the results. This can explain how digital thinking comes together, the major factors to look for in digital journey, and how they are all interlinked to create and establish the transformation. In this webinar, we give an insight into what Zifo has learned so far in its digital journey, as well as the industry trends that are in place and how they help with this digital journey. It also glances over a few minimal digital use cases which illustrate how the digital journey translates into systems. Following this, is an overview of Zifo as an organization and its business prospects in terms of expertise and value proposition.
Zifo
Waller D
1:30 PM CDT
Needle-to-Needle Cell and Gene Therapy
Gradalis is a clinical-stage biotechnology company whose mission is to develop a more effective treatment for cancer, using the patient’s immune system to target the entire complement of tumor neoantigens. The product life cycle begins with the collection of tumor tissue from the patient during standard of care cytoreductive surgery. Tissue is sent to Gradalis for product manufacture, testing, storage, verification of patient protocol eligibility, and product disposition. After release, verified product is distributed to and administered to the patient. Gradalis is further developing L7|ESP to provide patient identifiers that facilitate reporting of chain of identity and chain of custody from initial patient scheduling, through tissue collection and manufacturing, and during product shipments.
Ernest Bognar, Chief Operating Officer, Gradalis
Waller D
2:00 PM CDT
From Paper to Digital: Overcoming Challenges in Transitioning to a BioManufacturing Lab of the Future
The American Type Culture Collection (ATCC) is the world’s largest biological materials repository, and has provided the life sciences research community with critical reagents and biomaterials since 1925. In 2020, ATCC made the commitment to begin the journey towards a 100% digital, zero-paper biomanufacturing organization – a critical and transformative step in maintaining our industry leadership position as a standards setting organization. In this presentation, we will present our approach to beginning this journey and the progress we have made thus far. We will present some of the unique technical and infrastructure challenges our organization faces, our solutions to those challenges, and what challenges remain. Lastly, we will present our overall vision for our digital biology roadmap, and why digitalization of laboratories and manufacturing goes beyond improvements in quality, process, and throughput – but also creates new opportunities for commercial entities that were previously unreachable.
Jonathan Jacobs, Ph.D., Senior Director of Bioinformatics, ATCC
Waller D
2:30 PM CDT
Driving Commercial Launch Success with Digital Transformation
Leveraging in-market launch and transition experience, Jeff highlights key factors and components to having a CGT-centric digital platform. This session serves to demonstrate key success indicators of digital transformation, highlight other commercial launch enablers and explain what differentiates market leaders in digital transformation
Jeffrey Lacey, Senior Manager, Life Sciences, Deloitte
Waller D
3:00 PM CDT
Afternoon Coffee Networking
Foyer
3:30 PM CDT
Improving Assisted Reproduction Outcomes – State of the ART Preimplantation and Fertility Genetic Testing
As demand for fertility treatments, including Assisted Reproductive Technologies (ART) grow, there is increasing interest in fertility and pre-implantation genetic testing (PGT) as an approach to improve treatment success. In vitro fertilization coupled with diagnosing of hereditary diseases in embryos (PGT-M) emerges as a treatment option for genetic disorders that are progressively identified though implementation and wider adoption of carrier screening. CReATe Fertility Centre is internationally renowned for its specialized fertility services and personalized fertility treatment powered by CReATe Reproductive Genetics, a leader in developing and providing fertility and preimplantation genetic testing to improve patient management and increase success in ART. A steady 30% year-over-year growth in samples processed, over 20% increase in patients tested, diversification of genetic tests (eg. embryo testing PGT-A, PGT-M, PGT-SR, PGT-HLA, unsuccessful pregnancies – products of conception, patient fertility work up), and platforms used (eg Next Generation Sequencing-NGS, Long read sequencing, SNP arrays etc), maintaining high laboratory and regulatory standards highlighted the need for digitalization and effective operation support system. L7 ESP has enabled to integrate the clinical information from CReATe Electronic Medical Record (EMR) system, develop customized LIMS to support the end-to-end workflows of high throughput laboratory operations with multiple technology platforms, adopt automation of NGS for PGT, manage high dimensional data and reporting in a complex clinical setting. L7|ESP’s powerful audit trail and provenance history capabilities were essential in processing samples and in managing sample storage, inventory, and automating a multitude of important tasks from bar code printing to clinical report generation. Interactive development and implantation of L7|ESP LIMS and database system will prime the CReATe Reproductive genetics laboratory to handle and manage high throughput and growing activities.
Svetlana Madjunkova MD, PhD, Member, Board of Directors, Canadian Fertility and Andrology Society (CFAS), Member, Board of Directors, Preimplantation Genetic Diagnosis International Society (PGDIS), Adjunct Faculty, Department of Laboratory Medicine and Pathobiology, Temerty Faculty of Medicine, University of Toronto, Executive Director, CReATe Reproductive Genetics, Toronto, Canada
Waller D
4:00 PM CDT
Enabling the Life Sciences Value Chain: People – Data – Process – L7 Informatics
A complex life sciences environment demands a resilient value chain and transformed business model that break down data silos, reduce turnaround times, and place patients at the center of your operations. With an industry-wide connected value chain, data is readily available and accessible, which enables informed decision-making and quick reactions to disruptions in the supply chain. This also contributes to data integrity and on-time delivery of quality products. At the L7 Universe, GVW is present to discuss its approach towards a lifesciences value chain data backbone of the future by integrating People, Data Process, and L7 Informatics, delivering better business and patient outcomes.
Louis Hendriks, Founder and CEO, Global Value Web (GVW)
Waller D
4:15 PM CDT
Of Mice and Men: the Story of the Jackson Laboratory
Quantori will describe the collaborative work done with the Jackson Laboratory to develop and refine their laboratory technology infrastructure environments. The presentation will also share a high-level approach taken to implement L7|ESP to streamline operations and comply with evolving requirements for both commercial and research operations.
Arun Nayar, Global Head, R&D Informatics, Quantori
Waller D
4:30 PM CDT
L7 Roadmap
Learn more about what is in L7’s most recent release as well as where we are going over the next year.
Robert Ziegler, VP Product Development, L7 Informatics
Patrick Rose, Director of Product Management, L7 Informatics
Waller D
6:00 PM CDT
Dinner
The Roosevelt Room
wednesday, november 16
9:00 AM CDT
Panel Discussion: How do You Quantify Digital Success?
For companies grounded in the physical world, measuring the return on investment in digital is critical to pacing investment, but key performance indicators vary depending on the use case. In this panel, we’ll hear L7 customers discuss their approaches to quantifying success for their organizations across a range of initiatives including customer-facing digital solutions, digital customer experience, digitization of business operations and digital ways of working together.
Moderator:
Surekha Trivedi, VP Data Analytics & Strategy, Danaher
Panelists:
Brendan Arbuckle, Sr. Director, Research IT, The Jackson Laboratory
Ray Veeraraghavan, Executive Director – Advanced Diagnostics Technology, US,Quest Diagnostics
Jonathan Jacobs, Ph.D., Senior Director of Bioinformatics, ATCC
Waller D
10:00 AM CDT
Morning Coffee and Networking
Foyer
10:30 AM CDT
Translating Your Scientific Workflows into a Modern Digitalized Platform with Experienced Advocacy
With the many different functions within the lab, the ability to get the most out of your solution is critical. Leveraging powerful solutions such as L7 ESP will provide the flexibility to fill any gaps and improve your overall process.
Partnering with experienced professionals such as the team at Astrix avoids the need to learn how to be effective with an implementation. Even more valuable is the breadth of expertise, not only with your L7 implementation but across all the current market offerings. From this discussion we will look to cover:
• Ways to translate and improve your existing processes into the L7 ESP workflow capabilities
• How to properly augment your team for successful deployments
• Leveraging the proper guidance to prevent or correct the most common oversights
Adam Ryba, Director, LIS Delivery, Astrix
Waller D
10:50 AM CDT
How L7|ESP Has Enabled QIAGEN Laboratory Digitalization
L7|ESP is a powerful platform with features that accelerate the development of customized content, which supports a broad range of customer needs. L7|ESP streamlines lab-process execution and analysis pipelines, integrates with laboratory instrumentation, and provides a full chain-of-custody and audit trail from sample to report. L7|ESP also offers a role-based approval system and electronic signatures which are critical to meet Quality Assurance requirements.
Vikas Gupta, Associate Director, Global Bioinformatics and Software Development Lead at QIAGEN
Waller D
11:10 AM CDT
Using Innovative Microbial Genomic Techniques to Detect Pathogens Associated with Prosthetic Joint Infection
Prosthetic joint infections impart a large healthcare and personal burden, and their incidence has been increasing in the United States. Contamination Source Identification® (CSI) is working together with premier orthopedic institutions, including the Rothman Institute and Zimmer Biomet, to develop its own assay, CSI-Dx®, using proprietary RNA-targeted genomic sample preparation and bioinformatics annotation (RAPID-Dx®) techniques to detect PJIs. In a pilot study, CSI’s technology revealed distinct microbial communities between primary, aseptic, and infected synovial fluid samples using its own proprietary RNA sequencing assay. CSI-Dx® also identified pathogenic taxa in synovial fluid suspected to be infected in which current culture-based diagnostics failed.
Justin Wright, Co-Founder, Executive Vice President of Data Analytics, CSI-Dx / Wright Labs
Waller D
11:30 AM CDT
ESP in a High Throughput Diagnostic Genetics Lab
A start to implementation at GeneDx | sema4
Like many companies, GeneDx | sema4 has struggled to find or develop a single LIMS platform that can handle the volume, complexity, and change that is inherent in production life sciences. Third-party LIMS systems have been especially difficult to adopt due to lack of system performance at scale or copious amounts of customization that relied on vendor development. We endeavor to make L7|ESP the global solution that will manage and track all workflows within our high throughput and complex laboratory.
Our efforts to make L7|ESP the sole LIMS platform started with a Whole Genome Next Generation Sequencing workflow and ramped up to manage our entire DNA Extraction process. These processes need to handle plates of samples simultaneously and ease user workload by eliminating the burden of manually registering each sample. The methods highlight the ability work at scale with multiple technology platforms and also display the ability to handle exceptions to the high-volume pipeline in order to fully track the laboratory process.
Come explore how these two laboratory workflows are established for our high throughout genetics lab and the customizations that have made them successful. We’ll explore the makeup of these workflows and the custom APIs, protocol actions, pipelines, and applets that drive these processes. Additionally, we’ll discuss some insights into L7|ESP that we think could make the platform stronger for the high throughput environment and potentially help your own workflows.
Chad Walters, Associate Director of Informatics, Gene-Dx | Sema4
Waller D
12:00 PM CDT
Lunch
Foyer
1:00 PM CDT
Mphasis’ FHIR Based Interoperability Exchange
Mphasis, an applied technology company, has created an Interoperability exchange for connecting various entities in the healthcare and life sciences sector with different transaction standards so as to make systems/products/applications/instruments interoperable. The exchange can read different transaction formats like HL7, HIPAA X12, FHIR and creating a FHIR based lake. This not only provides a plug n play FHIR data interface to any system including L7 Informatics, but can also be used for patient/provider(HCP) experience or analytics.
Himanshu Gupta, Healthcare & Life Sciences Solutions Lead, Mphasis
Waller D
1:15 PM CDT
Mining Microbial Signatures Platform for New Diagnostics and Therapeutics Targets
Using an advanced metagenomics pipeline and advanced AI capabilities can revolutionize how biomarkers/drug targets are identified and validated in the clinic (Accuracy & Speed). BiotaX has developed a novel platform to identify & validate new microbial signatures that can be used as a noninvasive, early-stage diagnosis. BiotaX initial focus was on early-stage diagnosis of Colorectal Cancer & Pancreatic Cancer and companion diagnostic for immunotherapy checkpoint blockade treatments.
Shay Hilel, CEO, Biotax Labs LTD
Waller D
1:30 PM CDT
Unified Single-Cell Data Management with TileDB
Datasets generated by profiling single cells are growing rapidly in volume. The formats commonly used to distribute these data are not optimized for large volumes of data and cannot leverage cost effective cloud storage. Furthermore, choice of format is often determined by the language or analysis framework, creating silos of data that are difficult to share. To address these challenges, we have partnered with the Chan Zuckerberg Initiative to develop SOMA: a unified and open source solution for single-cell data. With TileDB-backed SOMA datasets, researchers can rapidly query and slice subsets of the data for analysis directly from the cloud and without downloading the entire dataset. We will demonstrate how the SOMA R and Python packages integrate directly with popular single-cell analysis frameworks like Seurat and Scanpy. And with TileDB Cloud researchers have a unified data management and analytics platform that provides data governance, simple sharing, and a serverless compute environment for scalable single-cell analysis.
Aaron Wolen, Principal Software Engineer, TileDB
Waller D
1:45 PM CDT
L7 & Tag.bio – A Data Mesh Architecture for Your L7 Data Assets
Tom Covington, CEO, Tag.bio
Waller D
2:00 PM CDT
Process Development using ELN on L7|ESP Platform
L7|ESP is changing the software landscape at Triumvira, helping to bring data from research, process dev, and, ultimately, manufacturing. Come here how they are going to start with the ELN and sample registration, to change the way they work.
Arnaud Deladeriere, Director of Process Development, Triumvira
Patrick Rose, Director of Product Management, L7 Informatics
Waller D
2:15 PM CDT
Customer Success Overview & Highlights
The success of our customers is top of mind for us. At L7 no one owns the customer, but someone always owns the moment. From our teams for Implementation, Customer Success, and Support, we strive daily to provide our customers with a consistent, predictable experience. Hear from Paul Wallace, Tom Ermlich, and Evan Payne on why 2023 is the year of Customer Success.
Paul Wallace, VP Customer Operations, L7 Informatics
Tom Ermlich, Sr. Practice Director, Professional Services, L7 Informatics
Evan Payne, Director of Customer Success, L7 Informatics
Waller D
2:45 PM CDT
L7 Masterclasses: What it’s About, and Who Should Attend
2022 has been a big year for L7 University. J.P. Brown will introduce the L7 University team, share our growing portfolio of offerings, and present how you can access them at our new University website. He will wrap up with a preview of offerings planned for 2023.
JP Brown, Director of Product Training, L7 Informatics
Waller D
3:00 PM CDT
Afternoon Coffee Networking
Foyer
3:30 PM CDT
L7 Product Session: Upcoming Applications
– Moving Your Processes, and Workflows with the L7|HUB
Brandon Varela, Scientific Technologist, Bioinformatics Applications, L7 Informatics
– Learning How to Make the Most of Your Data with L7|INTELLIGENCE
Patrick Rose, Director of Product Management, L7 Informatics
– Scheduling Your Work in L7|ESP
Megan Zimerman, Product Manager, L7 Informatics
– Using the Manufacturing Execution System (MES) with L7|ESP
Karri Unruh, Director of Product Management, L7 Informatics
– Using the Notebook Application in L7|ESP
Patrick Rose, Director of Product Management, L7 Informatics
Waller D
6:30 PM CDT
Dinner
Zanzibar
thank you to our partners
L7|UNIVERSE — celebrating our customers and partners in their journey to digital transformation
